Iteos Therapeutics Stock Annual Yield
| ITOS Stock | USD 8.55 0.01 0.12% |
Iteos Therapeutics fundamentals help investors to digest information that contributes to Iteos Therapeutics' financial success or failures. It also enables traders to predict the movement of Iteos Stock. The fundamental analysis module provides a way to measure Iteos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Iteos Therapeutics stock.
Iteos | Annual Yield |
Iteos Therapeutics Company Annual Yield Analysis
Iteos Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Iteos Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Iteos Therapeutics is extremely important. It helps to project a fair market value of Iteos Stock properly, considering its historical fundamentals such as Annual Yield. Since Iteos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iteos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iteos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Iteos Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Iteos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iteos Therapeutics from analyzing Iteos Therapeutics' financial statements. These drivers represent accounts that assess Iteos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iteos Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 667.2M | 1.2B | 1.6B | 694.3M | 624.9M | 692.5M | |
| Enterprise Value | 652.7M | 848.9M | 794.8M | 414.2M | 372.8M | 454.1M |
Iteos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iteos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iteos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Iteos Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | (170.82 M) | ||||
| Shares Outstanding | 36.53 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 99.29 % | ||||
| Number Of Shares Shorted | 2.21 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 8.92 X | ||||
| Revenue | 12.6 M | ||||
| Gross Profit | 267.63 M | ||||
| EBITDA | (151.1 M) | ||||
| Net Income | (112.64 M) | ||||
| Cash And Equivalents | 791.86 M | ||||
| Cash Per Share | 22.26 X | ||||
| Total Debt | 6.06 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.42 X | ||||
| Book Value Per Share | 17.29 X | ||||
| Cash Flow From Operations | (103.76 M) | ||||
| Short Ratio | 3.38 X | ||||
| Earnings Per Share | (3.14) X | ||||
| Target Price | 34.5 | ||||
| Number Of Employees | 157 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 312.36 M | ||||
| Total Asset | 667.59 M | ||||
| Retained Earnings | 124.63 M | ||||
| Working Capital | 510.64 M | ||||
| Net Asset | 667.59 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.